Clearwater Capital Advisors’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Clearwater Capital Advisors’s Portfolio GNOM Stock Details GNOM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-3,436	Closed	-$140K	–	156
2023 Q3	$140K	Buy	3,436 +44	+1%	+$2K	0.02%	136
2023 Q2	$164K	Sell	3,392 -418	-11%	-$20.9K	0.02%	143
2023 Q1	$188K	Hold	3,810	–	–	0.02%	146
2022 Q4	$193K	Buy	+3,810	New	+$196K	0.03%	151

Other funds holding GNOM

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

OCM

One Capital Management Westlake Village, California $3.65B AUM 15.32% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Lido Advisors Los Angeles, California $32.7B AUM 19.2% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

PGA

Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

IWM

IHT Wealth Management Chicago, Illinois $4.3B AUM 21.02% 1-Year Est. Return

SWA

Sightline Wealth Advisors Groton, Connecticut $273M AUM 18.08% 1-Year Est. Return

OAM

Oppenheimer Asset Management New York $8.76B AUM 23.12% 1-Year Est. Return

Clearwater Capital Advisors's GNOM Position: Q4 2023 in Review

Clearwater Capital Advisors sold out of Global X Genomics & Biotechnology ETF (GNOM) in Q4 2023, closing a stake of 3,436 shares — an estimated $140K sold.

Clearwater Capital Advisors first reported a position in GNOM in Q4 2022 and held it in 4 quarters. The position peaked at $193K in Q4 2022. 61 funds tracked by Wall St. Rank hold GNOM as of Q4 2023.

Clearwater Capital Advisors reported no remaining Global X Genomics & Biotechnology ETF position as of Q4 2023 after selling out during the quarter.
Clearwater Capital Advisors sold 3,436 Global X Genomics & Biotechnology ETF shares in Q4 2023, an estimated $140K.
Clearwater Capital Advisors first reported a position in Global X Genomics & Biotechnology ETF in Q4 2022 and held it in 4 quarters.
Clearwater Capital Advisors's Global X Genomics & Biotechnology ETF position peaked at $193K in Q4 2022.
61 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q4 2023.

Based on Clearwater Capital Advisors's 13F filing for Q4 2023, filed 7 Feb 2024.